Quick Answer
ROCKET PHARMACEUTICALS, INC. reported Operating Income Loss of -$231.75 million for the year ending 2025.
- ROCKET PHARMACEUTICALS, INC. showed an increase of +15.2% in Operating Income Loss from 2024 to 2025.
- This data is from ROCKET PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2014 to 2025), ROCKET PHARMACEUTICALS, INC.'s Operating Income Loss has declined by 2,908.1%.
- Historical annual values: Fiscal year 2025: -$231.75 million | Fiscal year 2024: -$273.21 million | Fiscal year 2023: -$259.66 million | Fiscal year 2022: -$224.34 million | Fiscal year 2021: -$167.25 million | Fiscal year 2020: -$134.30 million | Fiscal year 2019: -$76.15 million | Fiscal year 2018: -$71.16 million | Fiscal year 2017: -$19.77 million | Fiscal year 2016: -$7.57 million | Fiscal year 2015: -$20.40 million | Fiscal year 2014: -$7.70 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: